With 10.1% CAGR, Rapid Microbiology Testing Market to reach USD 16.91 Billion by 2035
Summary
The article outlines a strong growth outlook for the rapid microbiology testing market through 2035, driven by regulatory pressure, pharma lab automation, and faster diagnostic methods. It highlights how FDA and WHO compliance changes are pushing clinical and pharmaceutical labs toward automated, molecular, and mass-spectrometry-based workflows. It also points to bioMérieux’s acquisition of Accellix as an example of consolidation in the space. Vendors serving lab automation, life sciences software, and quality control should see expanding demand from pharma, biotech, and clinical laboratory buyers.
AskAI Classifications
Sectors
HealthTech
Manufacturing Industry
General Healthcare software
Functions
No functions detected
Linked Companies
bioMérieux
$1B+
Accellix
$5M to $10M